Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer (Q74358564)
Jump to navigation
Jump to search
scientific article published on 01 March 1998
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer |
scientific article published on 01 March 1998 |
Statements
Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer (English)
Orazi A
Hague NL
Sledge GW Jr
Rasmussen H
1 March 1998